Regencell Bioscience Holdings EBIT

Regencell Bioscience Holdings (RGC) currently reports a EBIT of $-15M as of June 2026. That compares with $-7.6M in the prior-year period — down 101.9% year over year. That is below the Healthcare sector average of $99B. Use the charts on this page to explore Regencell Bioscience Holdings's EBIT history and peer comparisons.

Regencell Bioscience Holdings's EBIT decreased from $-7.6M to $-15M — a 101.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Regencell Bioscience Holdings's EBIT of $-15M is lower than the Healthcare sector average of $99B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Regencell Bioscience Holdings reported $-15M in EBIT as of June 2026. That compares with $-7.6M in the prior-year period — down 101.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-15M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $99B. From there, open related valuation or income-statement pages for Regencell Bioscience Holdings, and consider following RGC for alerts when major investors trade the stock.